Catheter clot removal versus medicine alone after sudden lung artery blood clot
Compares catheter clot removal with medicine alone for long-term problems after pulmonary embolism.
Key facts
- Who runs it
- Assiut University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Post Pulmonary Embolism In Patients Treated With Catheter Based Therapy
- Status
- Not yet recruiting
- People taking part
- 120 people, planned
- Starts
- 1 Dec 2026
- Expected to end
- 30 Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- The Indigo aspiration system
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a sudden, serious blood clot in the lungs (acute pulmonary embolism). It compares clot removal through a catheter with medicine alone.
- Age
- 18 to 80 years
- Sex
- All sexes
- Disease stage
- Acute pulmonary embolism with symptoms for 14 days or less, confirmed on a CTPA scan with a clot in at least one main or proximal lobar lung artery. Category E, category D, or category C2/C3 by AHA guidelines: heart and lung failure, low blood pressure or shock, or higher risk with an abnormal right heart (RV) or abnormal heart blood tests.
- Biomarker or test result
- Category C2/C3 patients need an abnormal RV, abnormal cardiac biomarkers, or both.
Main reasons for not taking part
- Category A, B or C1 pulmonary embolism (no symptoms, low risk, or normal RV and heart blood tests)
- History or scans showing CTEPH or CTEPD
- Cannot take blood thinners, for example allergy or heparin induced thrombocytopenia, or active bleeding
- Contrast dye allergy that cannot be handled with medicine given beforehand
- Platelets <50,000/µL
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age 18-80 years old
- Clinical signs and symptoms consistent with acute PE with duration of 14 days or less
- Objectively confirmed acute PE, based on CTPA imaging showing a filling defect in at least one main or proximal lobar pulmonary artery
- Category E patients according to AHA recent guidelines for management of P.E including patients with cardiopulmonary failure states (either cardiac arrest, refractory cardiogenic shock or recurrent or persistent hypotension with cardiogenic shock)
- Category D patients (i.e patients with incipient cardiopulmonary failure) including normotensive shock with marker of decreased perfusion or end-organ dysfunction (eg, acute ischemic kidney injury, persistently elevated lactate) accompanied by transient hypotension and patients with transient or recurrent hypotension (including relative hypotension compared with the patient's baseline blood pressure) that is short-lived or responds to volume expansion and not accompanied by any signs of reduced perfusion or end-organ dysfunction
- Category C2,C3 patients with symptomatic disease with increased risk of adverse outcomes by validated severity index and either abnormal RV or abnormal cardiac biomarkers or both
- Femoral access deemed suitable for mechanical thrombectomy
- Informed consent is obtained from either the patient or legally authorized representative
Who cannot take part
- Category C1 patients with symptomatic disease with increased risk of adverse outcomes by validated severity index with normal RV and normal cardiac biomarkers
- Any known contraindication to anticoagulation including allergy, hypersensitivity, or heparin induced thrombocytopenia
- Active bleeding or disorders contraindicating anticoagulant therapy
- Platelets <50,000/µL
- Category A patients including asymptomatic and incidentally diagnosed PE cases
- Category B patients with symptomatic acute PE and low risk of adverse outcomes by validated severity indices
- History or imaging findings consistent with CTEPH or CTEPD diagnosis
- Contraindication or sensitivity to iodinated intravascular contrast that cannot be adequately premedicated
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Comparing the effects of the mechanical thrombectomy versus medical treatment alone on development and severity of post pulmonary embolism syndrome.
Read full original descriptionShow less
To define predictors of post pulmonary embolism syndrome. Incidence of category D and category E pulmonary embolism among P.E patients presenting by hemodynamic compromise.
Correlation with NEWS risk score (Respiratory rate, oxygen saturation, temperature, systolic blood pressure, heart rate, level of consciousness, and need for supplemental oxygen).
The 2 groups in the trial
- Catheter based therapy groupTreatment being tested
The Indigo aspiration system (Indigo Aspiration 8-16-F ® System, Penumbra, Alameda, CA, USA) is indicated for use in the peripheral arterial system and the pulmonary arteries, receiving U.S. Food and Drug Administration clearance for PE in December 2019. The PA will be accessed percutaneously, and a diagnostic pulmonary angiogram will be performed to evaluate hemodynamics. The aspiration catheter will be introduced over a 0.035-inch guidewire and advanced to the right or left PA, proximal to the thrombus. Once proximal to the occlusive thrombus, the physician will initiate sustained aspiration with the pump. If appropriate, the separator will be advanced through the catheter to assist with clearing the catheter lumen. Aspiration could be repeated in multiple pulmonary vessels with or without thrombus removal and flushing the catheter between passes. A final pulmonary angiogram and hemodynamic evaluation will be conducted post-Indigo device removal and post procedure.
Treatment: The Indigo aspiration system
- medical treatment aloneNo study treatment, for comparison
All patients will receive anticoagulation with either unfractionated heparin (UFH) or low-molecular-weight heparin as determined by the physician in accordance with current guidelines. Patients who will receive low-molecular-weight heparin will have it administered at a weight-/renal-adjusted therapeutic dose. The UFH bolus and infusion will be adjusted to achieve and maintain activated partial thromboplastin time corresponding to therapeutic heparin levels. All patients will be discharged on oral anticoagulation either NOAC or Warfarin for 6 months at least.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Post Pulmonary Embolism Functional Status And Quality Of Life In Patients Treated With Catheter Based Therapy
- Plain-language title
- Catheter clot removal versus medicine alone after sudden lung artery blood clotGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07885787, who can take part
- Record updated
- 21 October 2026